It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
TET2/3 play a well-known role in epigenetic regulation and mouse development. However, their function in cellular differentiation and tissue homeostasis remains poorly understood. Here we show that ablation of TET2/3 in intestinal epithelial cells results in a murine phenotype characterized by a severe homeostasis imbalance in the small intestine. Tet2/3-deleted mice show a pronounced loss of mature Paneth cells as well as fewer Tuft and more Enteroendocrine cells. Further results show major changes in DNA methylation at putative enhancers, which are associated with cell fate-determining transcription factors and functional effector genes. Notably, pharmacological inhibition of DNA methylation partially rescues the methylation and cellular defects. TET2/3 loss also alters the microbiome, predisposing the intestine to inflammation under homeostatic conditions and acute inflammation-induced death. Together, our results uncover previously unrecognized critical roles for DNA demethylation, possibly occurring subsequently to chromatin opening during intestinal development, culminating in the establishment of normal intestinal crypts.
DNA demethylation is known to be critical for the development and function of many tissues. Here the authors show that it is also required for intestinal lineage differentiation, and that mice lacking DNA demethylases have altered microbiomes and a predisposition to inflammation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Hebrew University Medical School, Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Jerusalem, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538)
2 German Cancer Research Center, Division of Epigenetics, DKFZ-ZMBH Alliance, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
3 The Weizmann Institute of Science, Department of Immunology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563); University Psychiatric Clinics Basel, Clinic for Adults, University of Basel, Basel, Switzerland (GRID:grid.6612.3) (ISNI:0000 0004 1937 0642)
4 The Weizmann Institute of Science, Department of Immunology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
5 Hebrew University Medical School, The Lautenberg Center for Immunology, Institute for Medical Research Israel-Canada, Jerusalem, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538)
6 The Weizmann Institute of Science, Department of Immunology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563); German Cancer Research Center (DKFZ), Division of Microbiome and Cancer, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)